1. Home
  2. AEF vs DSGN Comparison

AEF vs DSGN Comparison

Compare AEF & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AEF
  • DSGN
  • Stock Information
  • Founded
  • AEF 1989
  • DSGN 2017
  • Country
  • AEF United States
  • DSGN United States
  • Employees
  • AEF N/A
  • DSGN N/A
  • Industry
  • AEF Finance/Investors Services
  • DSGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • AEF Finance
  • DSGN Health Care
  • Exchange
  • AEF Nasdaq
  • DSGN Nasdaq
  • Market Cap
  • AEF 286.2M
  • DSGN 264.4M
  • IPO Year
  • AEF N/A
  • DSGN 2021
  • Fundamental
  • Price
  • AEF $5.25
  • DSGN $7.50
  • Analyst Decision
  • AEF
  • DSGN Hold
  • Analyst Count
  • AEF 0
  • DSGN 3
  • Target Price
  • AEF N/A
  • DSGN $7.00
  • AVG Volume (30 Days)
  • AEF 92.5K
  • DSGN 138.9K
  • Earning Date
  • AEF 01-01-0001
  • DSGN 11-07-2024
  • Dividend Yield
  • AEF 7.13%
  • DSGN N/A
  • EPS Growth
  • AEF N/A
  • DSGN N/A
  • EPS
  • AEF 0.57
  • DSGN N/A
  • Revenue
  • AEF N/A
  • DSGN N/A
  • Revenue This Year
  • AEF N/A
  • DSGN N/A
  • Revenue Next Year
  • AEF N/A
  • DSGN N/A
  • P/E Ratio
  • AEF $8.86
  • DSGN N/A
  • Revenue Growth
  • AEF N/A
  • DSGN N/A
  • 52 Week Low
  • AEF $4.40
  • DSGN $2.13
  • 52 Week High
  • AEF $5.53
  • DSGN $7.77
  • Technical
  • Relative Strength Index (RSI)
  • AEF 37.33
  • DSGN 76.03
  • Support Level
  • AEF $5.34
  • DSGN $5.32
  • Resistance Level
  • AEF $5.55
  • DSGN $6.20
  • Average True Range (ATR)
  • AEF 0.06
  • DSGN 0.46
  • MACD
  • AEF -0.02
  • DSGN 0.19
  • Stochastic Oscillator
  • AEF 0.00
  • DSGN 90.07

About AEF abrdn Emerging Markets Equity Income Fund Inc.

ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. It invests in the public equity and fixed income markets of Chile. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, Private Equity, telecommunication services, healthcare, real estate and industrials.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: